EASL Clinical Practice Guidelines on the Management of Benign Liver Tumors
Massimo Colombo – 7 May 2020
Nutrition Management Strategies for Nonalcoholic Fatty Liver Disease: Treatment and Prevention
Evelyn F. Miller – 7 May 2020
Isolated Elevated Bilirubin
Hersh Shroff, Haripriya Maddur – 7 May 2020
Preliminary Analysis of the Impact of the Coronavirus Disease 2019 Outbreak on Italian Liver Transplant Programs
Salvatore Gruttadauria, the Italian Board of Experts in Liver Transplantation (I‐BELT) Study Group, The Italian Society of Organ Transplantation (SITO) – 6 May 2020
REPLY
Liang Li, Yanpin Wei, Hongyang Wang – 6 May 2020
Liver Transplant Survivorship
Jennifer C. Lai, Nneka N. Ufere, John C. Bucuvalas – 6 May 2020 – For both children and adults with end‐stage liver disease, liver transplantation represents a lifelong treatment, not a cure. The physical and psychological process of undergoing transplantation begins well before the surgery itself. Concerns regarding suffering and death from end‐stage liver disease are replaced by a lifelong need for multiple medications, ongoing monitoring of graft function, and heightened vigilance for complications related not only to the transplant itself but to longterm immunosuppression.
C24‐Ceramide Drives Gallbladder Cancer Progression Through Directly Targeting Phosphatidylinositol 5‐Phosphate 4‐Kinase Type‐2 Gamma to Facilitate Mammalian Target of Rapamycin Signaling Activation
Yonglong Zhang, Hui Wang, Tao Chen, Haolu Wang, Xiaowen Liang, Yuchen Zhang, Jinlin Duan, Shenjiao Qian, Ke Qiao, Lei Zhang, Yanfeng Liu, Jian Wang – 6 May 2020
Changes in Liver Transplant Center Practice in Response to Coronavirus Disease 2019: Unmasking Dramatic Center‐Level Variability
Vatche Agopian, Elizabeth Verna, David Goldberg – 5 May 2020
Coronavirus Disease 2019 Hangover: A Rising Tide of Alcohol Use Disorder and Alcohol‐Associated Liver Disease
Ben L. Da, Gene Y. Im, Thomas D. Schiano – 5 May 2020 – The coronavirus disease 2019 (COVID‐19) pandemic has had a tremendous global impact since it began in November of 2019. However, there are concerns that the COVID‐19 pandemic will not affect all equally and that some populations will be particularly vulnerable. Relevant to liver disease, patients with alcohol use disorder (AUD) and alcohol‐associated liver disease (ALD) may be among the populations that are the most severely impacted.